Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Controversy exists regarding the potential regenerative influences of incretin therapy on pancreatic β-cells versus possible adverse pancreatic proliferative effects. Examination of pancreata from age-matched organ donors with type 2 diabetes mellitus (DM) treated by incretin therapy (n = 8) or other therapy (n = 12) and nondiabetic control subjects (n = 14) reveals an ∼40% increased pancreatic mass in DM treated with incretin therapy, with both increased exocrine cell proliferation (P < 0.0001) and dysplasia (increased pancreatic intraepithelial neoplasia, P < 0.01). Pancreata in DM treated with incretin therapy were notable for α-cell hyperplasia and glucagon-expressing microadenomas (3 of 8) and a neuroendocrine tumor. β-Cell mass was reduced by ∼60% in those with DM, yet a sixfold increase was observed in incretin-treated subjects, although DM persisted. Endocrine cells costaining for insulin and glucagon were increased in DM compared with non-DM control subjects (P < 0.05) and markedly further increased by incretin therapy (P < 0.05). In conclusion, incretin therapy in humans resulted in a marked expansion of the exocrine and endocrine pancreatic compartments, the former being accompanied by increased proliferation and dysplasia and the latter by α-cell hyperplasia with the potential for evolution into neuroendocrine tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Pancreatic, intestinal, and breast neoplasms were more frequently developed in rodents administered with incretin-based medications”
From Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? (2021) · cites this paper as [56]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“A decreased risk of colorectal adenomas and colorectal carcinoma is a consistent finding with a potential for a survival benefit for colorectal carcinoma.1784–1790”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1788]
Experimental — accuracy not yet measuredIn the citing paper
“these results were not confirmed in human studies [56–58].”
From Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? (2021) · cites this paper as [56]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Self-citationXu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Conversion of adult pancreatic α-cells to β-cells after extreme β-cell loss
Thorel, F., Népote, V., Avril, I., Kohno, K., Desgraz, R., Chera, S., & Herrera, P. L. (2010) · Nature · doi:10.1038/nature08894 · Cited by 1,136
Hruban, R. H., Takaori, K., Klimstra, D. S., Adsay, N. V., Albores-Saavedra, J., Biankin, A. V., Biankin, S. A., Compton, C., Fukushima, N., Furukawa, T., et al. (2004) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000126675.59108.80 · Cited by 1,091
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944
Self-citationZulewski, H., Abraham, E. J., Gerlach, M. J., Daniel, P. B., Moritz, W., Müller, B., Vallejo, M., Thomas, M. K., & Habener, J. F. (2001) · Diabetes · doi:10.2337/diabetes.50.3.521 · Cited by 785
Pancreatic β‐cell mass in European subjects with type 2 diabetes
Rahier, J., Guiot, Y., Goebbels, R. M., Sempoux, C., & Henquin, J. C. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00969.x · Cited by 756
Selective β-Cell Loss and α-Cell Expansion in Patients with Type 2 Diabetes Mellitus in Korea
Yoon, K. H., Ko, S. H., Cho, J. H., Lee, J. M., Ahn, Y. B., Song, K. H., Yoo, S. J., Kang, M. I., Cha, B. Y., Lee, K. W., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020735 · Cited by 649
Islet Pathology and the Pathogenesis of Type 1 and Type 2 Diabetes mellitus Revisited
Klöppel, G., Löhr, M., Habich, K., Oberholzer, M., & Heitz, P. U. (1985) · Pathology and Immunopathology Research · doi:10.1159/000156969 · Cited by 577
Gelling, R. W., Du, X. Q., Dichmann, D. S., Rømer, J., Huang, H., Cui, L., Obici, S., Tang, B., Holst, J. J., Fledelius, C., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0237106100 · Cited by 563
Cited by
Items 101–200 of 460
Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies
Bonner‐Weir, S., In't Veld, P. A., & Weir, G. C. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12257 · Cited by 54
Investigating G protein signalling bias at the glucagon‐like peptide‐1 receptor in yeast
Weston, C., Poyner, D., Patel, V, Dowell, S., & Ladds, G. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12716 · Cited by 53
Gut hormones as therapeutic agents in treatment of diabetes and obesity
Tan, T., & Bloom, S. R. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.09.005 · Cited by 66
The nonhuman primate as a model for type 2 diabetes
Pound, L. D., Kievit, P., & Grove, K. L. (2014) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000043 · Cited by 59
Lee, M., Sun, J., Han, M., Cho, Y., Lee, J., Nam, C. M., & Kang, E. S. (2019) · Diabetes Care · doi:10.2337/dc18-2195 · Cited by 58
Diabetes, antihyperglycemic medications and cancer risk: smoke or fire?
Gallagher, E. J., & LeRoith, D. (2013) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/01.med.0000433065.16918.83 · Cited by 53
Armstrong, M. J., Barton, D., Gaunt, P., Hull, D., Guo, K., Stocken, D., Gough, S. C. L., Tomlinson, J. W., Brown, R. M., Hübscher, S. G., et al. (2013) · BMJ Open · doi:10.1136/bmjopen-2013-003995 · Cited by 51
Increased Hormone-Negative Endocrine Cells in the Pancreas in Type 1 Diabetes
Moin, A. S. M., Dhawan, S., Shieh, C., Butler, P. C., Cory, M., & Butler, A. E. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1350 · Cited by 54
Self-citationMoin, A. S. M., Dhawan, S., Cory, M., Butler, P. C., Rizza, R. A., & Butler, A. E. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2496 · Cited by 56
Self-citationDiabetes and pancreatic neuroendocrine tumours: Which interplays, if any?
Gallo, M., Ruggeri, R. M., Muscogiuri, G., Pizza, G., Faggiano, A., & Colao, A. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.04.013 · Cited by 57
Does DPP-IV Inhibition Offer New Avenues for Therapeutic Intervention in Malignant Disease?
Bušek, P., Duke‐Cohan, J. S., & Šedo, A. (2022) · Cancers · doi:10.3390/cancers14092072 · Cited by 58
Should Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes?
Grunberger, G. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0853-8 · Cited by 54
Evolving function and potential of pancreatic alpha cells
Stanojevic, V., & Habener, J. F. (2015) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2015.10.002 · Cited by 59
An Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers
Tseng, C.-H., Lee, K.-Y., & Tseng, F.-H. (2015) · Journal of Environmental Science and Health, Part C · doi:10.1080/10590501.2015.1003496 · Cited by 49
Stress‐induced adaptive islet cell identity changes
Cigliola, V., Thorel, F., Chera, S., & Herrera, P. L. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12726 · Cited by 53
Jensen, T. M., Saha, K., & Steinberg, W. M. (2015) · Diabetes Care · doi:10.2337/dc13-1210 · Cited by 48
R. Drab, S. (2016) · Current Diabetes Reviews · doi:10.2174/1573399812666151223093841 · Cited by 47
Marquina-Sanchez, B., Fortelny, N., Farlik, M., Vieira, A., Collombat, P., Bock, C., & Kubicek, S. (2020) · Genome Biology · doi:10.1186/s13059-020-02006-2 · Cited by 50
Campbell-Thompson, M. (2015) · Pediatric Diabetes · doi:10.1111/pedi.12286 · Cited by 46
Self-citationMontilla, S., Marchesini, G., Sammarco, A., Trotta, M. P., Siviero, P. D., Tomino, C., Melchiorri, D., & Pani, L. (2014) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2014.07.014 · Cited by 49
The role of GLP-1 receptor agonists in managing type 2 diabetes
Nachawi, N., Rao, P. P., & Makin, V. (2022) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.89a.21110 · Cited by 45
New Insight on Human Type 1 Diabetes Biology: nPOD and nPOD-Transplantation
Pugliese, A., Vendrame, F., Reijonen, H., Atkinson, M. A., Campbell-Thompson, M., & Burke, G. W. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0530-0 · Cited by 45
Self-citationLiraglutide: A Review of Its Use in Adult Patients with Type 2 Diabetes Mellitus
Scott, L. J. (2014) · Drugs · doi:10.1007/s40265-014-0321-6 · Cited by 47
Use of incretin agents and risk of pancreatic cancer: a population‐based cohort study
Knapen, L. M., van Dalem, J., Keulemans, Y. C., van Erp, N. P., Bazelier, M. T., De Bruin, M. L., Leufkens, H. G. M., Croes, S., Neef, C., de Vries, F., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12605 · Cited by 43
The regulation of pre- and post-maturational plasticity of mammalian islet cell mass
Mezza, T., & Kulkarni, R. (2014) · Diabetologia · doi:10.1007/s00125-014-3251-7 · Cited by 48
Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis
Scheen, A. J. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.793671 · Cited by 47
Use of incretin agents and risk of acute and chronic pancreatitis: A population‐based cohort study
Knapen, L. M., de Jong, R. G. P. J., Driessen, J. H. M., Keulemans, Y. C. A., van Erp, N. P., Bruin, M. L. D., Leufkens, H. G. M., Croes, S., & de Vries, F. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12833 · Cited by 46
Liraglutide, a glucagon-like peptide-1 analog, induce autophagy and senescence in HepG2 cells
Krause, G. C., Lima, K. G., Dias, H. B., da Silva, E. F. G., Haute, G. V., Basso, B. D. S., Gassen, R. B., Marczak, E. S., Nunes, R. S. B., & de Oliveira, J. R. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.05.015 · Cited by 47
Umezawa, S., Kubota, A., Maeda, H., Kanamori, A., Matoba, K., Jin, Y., Minagawa, F., Obana, M., Iemitsu, K., Ito, S., et al. (2015) · BMC Endocrine Disorders · doi:10.1186/s12902-015-0033-2 · Cited by 42
High fat diet and GLP-1 drugs induce pancreatic injury in mice
Rouse, R. L., Xu, L., Stewart, S. R., & Zhang, J. (2014) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2014.01.021 · Cited by 46
Ryder, R. E. J. (2013) · Diabetic Medicine · doi:10.1111/dme.12301 · Cited by 41
Obesity, diabetes, and cancer: epidemiology, pathophysiology, and potential interventions
Mesquita, L. D. A., Wayerbacher, L. F., Schwartsmann, G., & Gerchman, F. (2023) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000647 · Cited by 52
Enteroendocrine hormone mimetics for the treatment of obesity and diabetes
Irwin, N., & Flatt, P. R. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.09.009 · Cited by 41
Alogliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
Keating, G. M. (2015) · Drugs · doi:10.1007/s40265-015-0385-y · Cited by 42
Intestinal mTOR regulates GLP-1 production in mouse L cells
Xu, G., Li, Z., Ding, L., Tang, H. W., Guo, S., Liang, H., Wang, H., & Zhang, W. (2015) · Diabetologia · doi:10.1007/s00125-015-3632-6 · Cited by 41
Wen, J., Nadora, D., Bernstein, E., How-Volkman, C., Truong, A., Joy, B., Kou, M., Muttalib, Z., Alam, A., & Frezza, E. E. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70113 · Cited by 53
Glucagon-Like Peptide-1 Receptor Agonists for Diabetes Mellitus: A Role in Cardiovascular Disease
Smilowitz, N. R., Donnino, R. M., & Schwartzbard, A. Z. (2014) · Circulation · doi:10.1161/circulationaha.113.006985 · Cited by 43
Pancreatic α-Cell Hyperplasia: Facts and Myths
Yu, R. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2952 · Cited by 39
Consoli, A., Formoso, G., Baldassarre, M. P. A., & Febo, F. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1428305 · Cited by 37
A direct look at the dysfunction and pathology of the β cells in human type 2 diabetes
Marchetti, P., Suleiman, M., Luca, C. D., Baronti, W., Bosi, E., Tesi, M., & Marselli, L. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.04.005 · Cited by 46
Cao, M., Pan, C., Tian, Y., Wang, L., Zhao, Z., & Zhu, B. (2023) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-023-01556-2 · Cited by 40
Mondragon, A., Davidsson, D., Kyriakoudi, S., Bertling, A., Gomes-Faria, R., Cohen, P., Rothery, S., Chabosseau, P., Rutter, G. A., & da Silva Xavier, G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104873 · Cited by 37
Marchetti, P., Suleiman, M., & Marselli, L. (2018) · Diabetologia · doi:10.1007/s00125-018-4546-x · Cited by 41
Chadwick, K. D., Fletcher, A. M., Parrula, M. C., Bonner-Weir, S., Mangipudy, R. S., Janovitz, E., Graziano, M. J., Roy, D., & Reilly, T. P. (2014) · Diabetes · doi:10.2337/db13-1268 · Cited by 37
Aston-Mourney, K., Subramanian, S. L., Zraika, S., Samarasekera, T., Meier, D. T., Goldstein, L. C., & Hull, R. L. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00025.2013 · Cited by 37
Incretin-based therapies in prediabetes: Current evidence and future perspectives
Papaetis, G. S. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i6.817 · Cited by 37
Bušek, P., Hrabal, P., Fric, P., & Šedo, A. (2014) · Histochemistry and Cell Biology · doi:10.1007/s00418-014-1292-0 · Cited by 39
Comparative effectiveness of liraglutide in the treatment of type 2 diabetes
Fadini, G. P., & Rigato, M. (2014) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s37644 · Cited by 36
Dipeptidyl peptidase-4 inhibitors: Anti-diabetic drugs with potential effects on cancer
Almagthali, A., Alkhaldi, E. H., Alzahrani, A. S., Alghamdi, A. K., Alghamdi, W. Y., & Kabel, A. M. (2018) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2018.08.012 · Cited by 41
International Journal of Chemistry and Pharmaceutical Sciences
Dhani, P. R. (2014) · ADVANCED SCIENCES INDEX · Cited by 36
Frequency of cancer events with saxagliptin in the SAVOR‐TIMI 53 trial
Leiter, L. A., Teoh, H., Mosenzon, O., Cahn, A., Hirshberg, B., Stahre, C., Hoekstra, J. B. L., Alvarsson, M., Im, K., Scirica, B. M., et al. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12582 · Cited by 35
Schwasinger-Schmidt, T. E., Robbins, D. C., Williams, S. J., Novikova, L., & Stehno‐Bittel, L. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.07.005 · Cited by 35
Incretin-based therapies for obesity treatment
de Mello, A. H., Prá, M. D., Cardoso, L. C., Schraiber, R. D. B., & Rezin, G. T. (2015) · Metabolism · doi:10.1016/j.metabol.2015.05.012 · Cited by 36
Safety of antidiabetes medications: An update
Bailey, C. J. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.125 · Cited by 33
Jun, L. S., Showalter, A. D., Ali, N., Dai, F., Ma, W., Coskun, T., Ficorilli, J. V., Wheeler, M. B., Michael, M. D., & Sloop, K. W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093746 · Cited by 32
Shi, S., He, Y., Koya, D., & Kanasaki, K. (2014) · Journal of Diabetes Investigation · doi:10.1111/jdi.12208 · Cited by 35
Incretins, Diabetes, Pancreatitis and Pancreatic Cancer: What the GI specialist needs to know
Forsmark, C. E. (2015) · Pancreatology · doi:10.1016/j.pan.2015.11.009 · Cited by 35
Extra-pancreatic effects of incretin-based therapies
Gallwitz, B. (2014) · Endocrine · doi:10.1007/s12020-014-0223-0 · Cited by 35
Relevance of beta-cell function for improved glycemic control after gastric bypass surgery
Blanco, J., Jiménez, A., Casamitjana, R., Flores, L., Lacy, A. M., Conget, I., & Vidal, J. (2013) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2013.07.020 · Cited by 33
Chalmer, T., Almdal, T. P., Vilsbøll, T., & Knop, F. K. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.975205 · Cited by 31
Nakamura, T., Ito, T., Uchida, M., Hijioka, M., Igarashi, H., Oono, T., Kato, M., Nakamura, K., Suzuki, K., Jensen, R. T., et al. (2013) · Laboratory Investigation · doi:10.1038/labinvest.2013.133 · Cited by 33
An Analysis of Characteristics of Subjects Examined for Incretin Effects on Pancreatic Pathology
Harja, E., Lord, J., & Skyler, J. S. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0177 · Cited by 30
Fransson, L., dos Santos, C., Wolbert, P., Sjöholm, Å., Rafacho, A., & Ortsäter, H. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-3 · Cited by 34
Singh, A. K., Gangopadhyay, K. K., & Singh, R. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1736041 · Cited by 33
Ilievski, V., Tóth, P. T., Valyi‐Nagy, K., Vályi-Nagy, T., Green, S. J., Marattil, R. S., Aljewari, H. W., Wicksteed, B. L., O’brien-simpson, N. M., Reynolds, E. C., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-65828-x · Cited by 37
Renner, S., Blutke, A., Streckel, E., Wanke, R., & Wolf, E. (2015) · The Journal of Pathology · doi:10.1002/path.4655 · Cited by 35
Wang, H., Liu, Y., Tian, Q., Yang, J., Lu, R., Zhan, S., Haukka, J. K., & Hong, T. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13177 · Cited by 36
Synergistic anti-tumor effects of liraglutide with metformin on pancreatic cancer cells
Lu, R., Yang, J., Wei, R., Ke, J., Tian, Q., Yu, F., Liu, J., Zhang, J., & Hong, T. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198938 · Cited by 30
Hidayat, K., Zhou, Y., Du, H., Qin, L., Shi, B., & Li, Z. (2022) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5550 · Cited by 32
Human pancreatic α‐ to β‐cell area ratio increases after type 2 diabetes onset
Fujita, Y., Kozawa, J., Iwahashi, H., Yoneda, S., Uno, S., Eguchi, H., Nagano, H., Imagawa, A., & Shimomura, I. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12841 · Cited by 34
Incretin-based therapy and pancreatitis: accumulating evidence and unresolved questions
Saisho, Y. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.02.24 · Cited by 31
Single-cell transcriptomics from human pancreatic islets: sample preparation matters
Bonnycastle, L. L., Gildea, D. E., Yan, T., Narisu, N., Swift, A. J., Wolfsberg, T. G., Erdos, M. R., & Collins, F. S. (2019) · Biology Methods and Protocols · doi:10.1093/biomethods/bpz019 · Cited by 27
The double trouble of metabolic diseases: the diabetes–cancer link
Tudzarova, S., & Osman, M. A. (2015) · Molecular Biology of the Cell · doi:10.1091/mbc.e14-11-1550 · Cited by 26
Glucagon receptor gene mutations with hyperglucagonemia but without the glucagonoma syndrome
Miller, H. C., Kidd, M. S., Modlin, I. M., Cohen, P., Dina, R. E., Drymousis, P., Vlavianos, P., Klöppel, G., & Frilling, A. (2015) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v7.i4.60 · Cited by 27
Kirk, R. K., Pyke, C., von Herrath, M. G., Hasselby, J. P., Pedersen, L., Mortensen, P. G., Knudsen, L. B., & Coppieters, K. T. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12879 · Cited by 28
Streckel, E., Braun-Reichhart, C., Herbach, N., Dahlhoff, M., Keßler, B., Blutke, A., Bähr, A., Übel, N., Eddicks, M., Ritzmann, M., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0431-2 · Cited by 29
Lamont, B. J., & Andrikopoulos, S. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0577 · Cited by 28
The rationale for combining GLP‐1 receptor agonists with basal insulin
Cohen, N. D., Audehm, R. G., Pretorius, E., Kaye, J. M., Chapman, L. H., & Colagiuri, S. (2013) · The Medical Journal of Australia · doi:10.5694/mja12.11856 · Cited by 25
The Role of Common Pharmaceutical Agents on the Prevention and Treatment of Pancreatic Cancer
Amin, S., Boffetta, P., & Lucas, A. L. (2016) · Gut and Liver · doi:10.5009/gnl15451 · Cited by 25
Ueki, K., Tanizawa, Y., Nakamura, J., Yamada, Y., Inagaki, N., Watada, H., Shimomura, I., Nishimura, R., Miyoshi, H., Abiko, A., et al. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001787 · Cited by 27
Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors
Tomkin, G. H. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i5.636 · Cited by 24
Lixisenatide: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
Scott, L. J. (2013) · BioDrugs · doi:10.1007/s40259-013-0057-y · Cited by 26
Natalicchio, A., Faggiano, A., Zatelli, M. C., Argentiero, A., D’Oronzo, S., Marrano, N., Beretta, G. D., Acquati, S., Adinolfi, V., Bartolo, P. D., et al. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103572 · Cited by 27
Regeneration of pancreatic insulin-producing cells by in situ adaptive cell conversion
Chera, S., & Herrera, P. L. (2016) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2016.05.010 · Cited by 26
Tseng, C., Liao, W., Chang, C., Lee, C., Tseng, C., Hsu, Y., & Lin, J. (2016) · Pancreatology · doi:10.1016/j.pan.2016.10.003 · Cited by 24
Chen, H., Zhou, X., Chen, T., Liu, B., Jin, W., Gu, H., Hong, T., & Zhang, G. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0198-3 · Cited by 24
Muhammed, A., Thomas, C., Kalaiselvan, V., & Undela, K. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2284992 · Cited by 25
Role of SGLT2 Inhibitors, DPP-4 Inhibitors, and Metformin in Pancreatic Cancer Prevention
Laeeq, T., Ahmed, M., Sattar, H., Zeeshan, M. H., & Ali, M. B. (2024) · Cancers · doi:10.3390/cancers16071325 · Cited by 24
Peering Into the “Black Box” of the Complex Chronic Pancreatitis Syndrome
Whitcomb, D. C. (2016) · Pancreas · doi:10.1097/mpa.0000000000000715 · Cited by 24
The required beta cell research for improving treatment of type 2 diabetes
Thorens, B. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12096 · Cited by 26
Tirzepatide—Friend or Foe in Diabetic Cancer Patients?
Samuel, S. M., Varghese, E., Kubatka, P., & Büsselberg, D. (2022) · Biomolecules · doi:10.3390/biom12111580 · Cited by 24
AACE Comprehensive Diabetes Management Algorithm 2013 Endocrine Practice
Tamez-Pérez, H. E., Peña, S. L. P., & Hernández-Coria, M. I. (2013) · Endocrine Practice · doi:10.4158/ep13210.lt · Cited by 22
Incretin based therapy and pancreatic cancer: Realising the reality
Suryadevara, V., Roy, A., Sahoo, J., Kamalanathan, S., Naik, D., Mohan, P., & Kalayarasan, R. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i25.2881 · Cited by 23
Chai, S., Yu, S., Yang, Z., Wu, S., Gao, L., Wang, H., Zhang, Y., Zhan, S., Ji, L., & Sun, F. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000728 · Cited by 22
A pooled analysis of exenatide use and risk of acute pancreatitis
Dore, D. D., Hussein, M., Hoffman, C., Pelletier, E. M., Smith, D. B., & Seeger, J. D. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.838550 · Cited by 21
Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes
Raskin, P., & Mann, K. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s35331 · Cited by 26
Fiorentino, T. V., Owston, M. A., ABRAHAMIAN, G. A., Rosa, S. L., Marando, A., Perego, C., Cairano, E. S. D., Finzi, G., Capella, C., Sessa, F., et al. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.09.009 · Cited by 21
Sadhu, A., Schwartz, S. S., & Herman, M. E. (2015) · Endocrine Practice · doi:10.4158/ep14569.ra · Cited by 23
Pancréatites d’origine médicamenteuse. Revue des notifications spontanées en France
Chebane, L., Bagheri, H., Hillaire‐Buys, D., Geniaux, H., Yahioui, N., Laroche, M., Cottin, J., Spreux, A., Mosquet, B., Pécriaux, C., et al. (2015) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2015.04.012 · Cited by 24
Co-localization of acinar markers and insulin in pancreatic cells of subjects with type 2 diabetes
Masini, M., Marselli, L., Himpe, E., Martino, L., Bugliani, M., Suleiman, M., Boggi, U., Filipponi, F., Occhipinti, M., Bouwens, L., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179398 · Cited by 21
Metadata
- Authors
- Butler, A. E., Campbell-Thompson, M., Gurlo, T., Dawson, D. W., Atkinson, M., & Butler, P. C.
- Affiliations
- University of California, Los Angeles (US)
- Departments of Pathology and Pediatrics, College of Medicine, University of Florida, Gainesville, Florida.
- University of Florida Health (US)
- Corresponding author
- Butler, Alexandra E.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2013-06-14
- Volume
- 62
- Issue
- 7
- Pages
- 2595-2604
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3712065
- OpenAlex
- W2137982063
- Cited by
- 457
- References
- 35
- Citations by year
- 2026: 18 · 2025: 20 · 2024: 15 · 2023: 12 · 2022: 19 · 2021: 16 · 2020: 20 · 2019: 21 · 2018: 19 · 2017: 25 · 2016: 34 · 2015: 59 · 2014: 99 · 2013: 80
- FWCI
- 90.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc-nd)
- Funders
- Larry L. Hillblom Foundation
- National Institute of Diabetes and Digestive and Kidney Diseases (DK-061539, R01DK061539, DK059579, #DK077967, R01DK077967, R01DK059579)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Keywords
- incretin-based therapy, beta-cell mass, pancreatic intraepithelial neoplasia, alpha cell hyperplasia, type 2 diabetes, pancreatic regeneration
- MeSH terms
- Sitagliptin Phosphate, Adenoma, Adolescent, Adult, Aged, Diabetes Mellitus, Type 2, Female, Humans, Hyperplasia, Male, Middle Aged, Organ Size, Pancreas, Pyrazines, Triazoles, Neuroendocrine Tumors, Cell Proliferation, Insulin-Secreting Cells, Incretins, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.